Ivermectin Combined With Recombinant Methioninase (rMETase) Synergistically Eradicates MiaPaCa-2 Pancreatic Cancer Cells DOI Creative Commons
Sei Morinaga,

QINGHONG HAN,

KOHEI MIZUTA

et al.

Anticancer Research, Journal Year: 2024, Volume and Issue: 45(1), P. 97 - 103

Published: Dec. 30, 2024

Background/Aim: Ivermectin was initially utilized as a veterinary medication, demonstrating efficacy against various parasites. Pancreatic cancer is currently one of the most recalcitrant diseases. The aim present study to demonstrate synergy combination recombinant methioninase (rMETase) and ivermectin eradicate human pancreatic cells in vitro. Materials Methods: MiaPaCa-2 were cultured Dulbecco's modified Eagle's medium (DMEM) with addition 10% fetal bovine serum 1 IU/ml penicillin/streptomycin. Reduction cell viability by rMETase alone their on determined WST-reagent. Four experimental groups examined vitro: control group without treatment; alone; combined rMETase. Results: IC50 for 5.9 μM. 2.93 U/ml. (5.9 μM) plus (2.93 U/ml) synergistically greatly reduced cells, compared (80% reduction vs. 45% reduction, respectively p<0.05). Conclusion: effectively eradicated cells. results indicate future clinical potential rMETase, administered orally patients dietary supplement, oral cancer.

Language: Английский

Synergistic Eradication of Fibrosarcoma With Acquired Ifosfamide Resistance Using Methionine Restriction Combined With Ifosfamide in Nude-mouse Models DOI Open Access
Sei Morinaga,

QINGHONG HAN,

KOHEI MIZUTA

et al.

In Vivo, Journal Year: 2024, Volume and Issue: 39(1), P. 120 - 126

Published: Dec. 31, 2024

Ifosfamide is used clinically with doxorubicin as first-line chemotherapy for soft-tissue sarcoma. However, ifosfamide efficacy sarcoma limited due to frequent occurence of resistance and thus more effective therapy needed. The present study aimed determine the synergy recombinant methioninase (rMETase) plus against HT1080 human fibrosarcoma cells in vitro. Additionally, also investigated a methionine-restricted diet combined nude-mouse models ifosfamide-resistant (IR-HT1080).

Language: Английский

Citations

0
Ivermectin Combined With Recombinant Methioninase (rMETase) Synergistically Eradicates MiaPaCa-2 Pancreatic Cancer Cells DOI Creative Commons
Sei Morinaga,

QINGHONG HAN,

KOHEI MIZUTA

et al.

Anticancer Research, Journal Year: 2024, Volume and Issue: 45(1), P. 97 - 103

Published: Dec. 30, 2024

Background/Aim: Ivermectin was initially utilized as a veterinary medication, demonstrating efficacy against various parasites. Pancreatic cancer is currently one of the most recalcitrant diseases. The aim present study to demonstrate synergy combination recombinant methioninase (rMETase) and ivermectin eradicate human pancreatic cells in vitro. Materials Methods: MiaPaCa-2 were cultured Dulbecco's modified Eagle's medium (DMEM) with addition 10% fetal bovine serum 1 IU/ml penicillin/streptomycin. Reduction cell viability by rMETase alone their on determined WST-reagent. Four experimental groups examined vitro: control group without treatment; alone; combined rMETase. Results: IC50 for 5.9 μM. 2.93 U/ml. (5.9 μM) plus (2.93 U/ml) synergistically greatly reduced cells, compared (80% reduction vs. 45% reduction, respectively p<0.05). Conclusion: effectively eradicated cells. results indicate future clinical potential rMETase, administered orally patients dietary supplement, oral cancer.

Language: Английский

Citations

0